Dexcom G7 is clinically proven to improve glycemic outcomes1-5
- >1% A1C reduction after 12 weeks1,2,5
- >1 hour increase in time in range for T1D and T2D after 12 weeks1,2
- Features to reduce rebound hyper- and hypoglycemia6-8
Patients using Dexcom CGM resulted in:
- 35% (~$358 PPPM) reduced diabetesrelated inpatient admission costs9
- ~50% reduced diabetesrelated inpatient visits10
CGM = continuous glucose monitoring; PPPM = per patient per month; T1D = type 1 diabetes; T2D = type 2 diabetes.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. 1 Beck RW, et al. JAMA. 2017;317(4):371-378. 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 3 Martens T, et al. JAMA. 2021;325(22):2262-2272. 4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 6 Dexcom G7 User Guide, 2023. 7 Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677-682. 8 Wilmot E. Dexcom G7: Unique Features and Correlational Improvements in Glycemic Control. Presented at the 16th International ATTD Conference on February 23, 2023. 9 Norman GJ, et al. Diabetes Technol Ther. 2022;24(7):520-524. 10 Hannah K, et al. Diabetes. 2023;72(Suppl 1):991-P. Dexcom and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2024 Dexcom, Inc. All rights reserved. MAT-4717
